drugset
drugset / Trial / NCT01952561

Expanded Use PK of Dapivirine Vaginal Ring

NCT01952561 ↗

Phase 1 Completed 40 enrolled International Partnership for Microbicides, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

Study will evaluate the vaginal and blood pharmacokinetics of dapivirine from a vaginal ring containing 25 mg worn for 1, 2, 4, 8 or 12 months.

Timeline

Start
2013-11
Primary completion
2014-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject dapivirine Small molecule 25 mg Other

Indications

No indication recorded.